MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergics"

  • 2017 International Congress

    Direct dopaminergic responsiveness of activity performance

    P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

    Objective: To assess the direct dopaminergic responsiveness of motor and process aspects of activity performance in people with parkinsonian disorders, and to compare this to…
  • 2017 International Congress

    Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.

    B. Schroeder, E. Thomas, T. Williams, S. Mahon, B. Mohamed (Cardiff, United Kingdom)

    Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…
  • 2017 International Congress

    Effects of dopaminergic medication on executive function in Parkinson’s disease differs according to the clinical stage

    H. Murakami, M. Kezuka, R. Kon, M. Kawamura, K. Ono (Tokyo, Japan)

    Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on…
  • 2016 International Congress

    Duodopa for the treatment of severe restless legs syndrome

    J. Perez-Perez, B. Pascual-Sedano, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

    Objective: To describe the outcome of a patient with restless legs syndrome (RLS) and augmentation phenomena that was treated with Duodopa in continuous infusion. Background:…
  • 2016 International Congress

    Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

    J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

    Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…
  • 2016 International Congress

    Parkinson’s disease patients with onset in right side have a worse cognitive prognosis

    T. Poliakova, I. Zerr, O. Levin (Belgorod, Russia)

    Objective: The our intention was to investigate a dynamics of cognitive decline in patients with different side of onset parkinsonism in view of visual dysfunction…
  • 2016 International Congress

    Illusional perception in Parkinson’s disease

    C. Ding, C. Palmer, J. Hohwy, G. Youssef, B. Paton, N. Tsuchiya, J. Stout, D. Thyagarajan (Clayton, Australia)

    Objective: To investigate (a) whether a susceptibility to illusional perceptions is intrinsic to Parkinson's disease even before the onset of hallucinations or cognitive impairment and…
  • 2016 International Congress

    Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

    A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

    Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
  • 2016 International Congress

    Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

    T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

    Objective: To investigate the effect of levodopa on articulatory movement during Cantonese plosive production in individuals with Parkinson's disease (PD) by comparing kinematic parameters before…
  • 2016 International Congress

    Supplement use in PD is associated with delayed initiation of dopaminergic therapy

    L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

    Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley